International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(1):24-29.

The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD following Hematopoietic Stem Cell Transplantation
Seyed Asadollah Mousavi, Mina Javadimoghadam, Ardeshir Ghavamzadeh, Kamran Alimoghaddam, Azadeh Sayarifard, Seyed-Hamidollah Ghaffari, Bahram Chahardouli, Ali Basi


Background: The study attempts to assess the relationship between chimerism analysis using polymerase chain reaction of short tandem repeat (STR) and the incidence of chronic graft versus host disease (GvHD) as well as survival.

Methods: The retrospective cohort included all patients who received allo-HSCT between 2005 to 2013. Data collected by day +100 were reviewed in terms of the incidence of chronic GvHD and survival. Chimerism was evaluated for whole blood, T-cell and PMN cells on days 15, 30 and 60, respectively using polymerase chain reaction of short tandem repeat (STR).

Results: Forty (69%) patients developed chronic GvHD, 11 (19%) relapsed and 22 (39.7%) died during the study. There was a significant relationship between chronic GvHD and chimerism analysis including whole blood on day 60 (P=0.001), PMN on day 60 (p= 0.05) and T-cell on days 15 (p=0.028), 30(p=0.01) and 60 (p=0.004). Patients with chronic GvHD showed a long-term survival as compared with those without chronic GvHD (P=0.0013).

Conclusion: Conducting continuous analysis of chimerism provides an opportunity to initiate immediate measures to prevent complications.


Hematopoietic Stem Cell Transplantation; Chronic GvHD; chimerism; polymerase chain reaction

Full Text:



Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin. 2011; 61(2): 69-90.

Thiede C, Bornhäuser M, Oelschlägel U, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia. 2001; 15(2):293-302.

Sufliarska S, Minarik G, Horakova J, et al. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin. Neoplasma. 2007; 54(5):424-30.

Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000, 8(1): 33-9.

Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008; 41 Suppl 2:S58-64.

Passweg J, Zhang MJ, Rocha V, et al. Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. Biol Blood Marrow Transplant. 2011; 17(12):1869-73.

Jiang Y, Wan L, Qin Y, et al. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One. 2015; 10(7):e0133671.

Cobbold SP, Li XC. Translating Tolerogenic Therapies to the Clinic-Where Do We Stand and What are the Barriers? Front Immunol. 2012; 3:317.

Szyska M, Na IK. Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol.2016; 7:118.

Spencer GD, Hackman RC, McDonald GB, et al. A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation. 1986; 42(6):602-7.

Yi T , Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009; 114(14): 3101-12.

Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003; 349(23):2201-10.

Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients whodevelop acute GVHD. Bone Marrow Transplant. 1995; 15(1):99-104.

Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17.

Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991; 28(3):250-9.

Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990; 75(12):2459-64.

Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004; 125(4):435-54.

Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in humanrecipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4): 295-304.

Barta A, Bátai A, Kelemen E, et al. Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Hum Immunol. 2000; 61(2):101-10.

Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 7(9):473-85.

Drexler C, Wagner T. Blood group chimerism. Curr Opin Hematol. 2006; 13(6): 484-9.

Pasquet L, Joffre O, Santolaria T, et al. Hematopoietic Chimerism and Transplantation Tolerance: A Role for Regulatory T Cells. Front Immunol. 2011; 2:80.

Goh RY, Cho SS, Song YJ, et al. Clinical Utility of Chimerism Status Assessed by Lineage-Specific Short Tandem Repeat Analysis: Experience from Four Cases of Allogeneic Stem Cell Transplantation. Korean J Lab Med. 2009; 29(4):277-81.

Sairafi D, Remberger M, Uhlin M, et al. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant.2010; 16(12): 1728-37.

Goh RY, Kim SH, Han JY. Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablativeallogeneic hematopoietic stem cell transplantation. Korean J Hematol. 2011; 46(1):18-23.

Lee HC, Saliba RM, Rondon G, et al. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015; 21(11):1948-54.

Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant 2005; 35(2): 107-19.

Petz LD, Yam P, Wallace RB, et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood. 1987; 70(5):1331-7.

Spyridonidis A, Zeiser R, Wäsch R, et al. Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation. Clinical Transplantation. 2005; 19(3):350-6.

Jaksch M, Uzunel M, Remberger M, et al. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II–IV. Clin Transplant. 2005; 19(3): 346–9.

Alimoghaddam K, Ghaffari H, Foroughi F, et al. Effects of chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation in Iran. Arch Iran Med. 2006; 9(2):99-103.

Balon J, Ha’aburda K, Bieniaszewska M, et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant. 2005; 35(11):1083-8.

Barrios M, Jimenez-Velasco A, Roman-Gomez J, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003; 88(7):801-10.

Rupa-Matysek J, Lewandowski K, Nowak W, et al. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2011; 43(5):1915-23.

Mossallam GI, Kamel AM, Storer B, et al. Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15(3):352-9.

Pérez-Simón JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol. 2003; 121(1):104-8.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.